DNB Asset Management AS Raises Position in Exact Sciences Corporation $EXAS

DNB Asset Management AS boosted its position in Exact Sciences Corporation (NASDAQ:EXAS) by 15.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 246,639 shares of the medical research company’s stock after purchasing an additional 33,071 shares during the period. DNB Asset Management AS owned about 0.13% of Exact Sciences worth $13,494,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Great Lakes Advisors LLC lifted its holdings in shares of Exact Sciences by 3.7% in the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after buying an additional 178 shares during the period. Capital Asset Advisory Services LLC grew its holdings in Exact Sciences by 4.8% during the third quarter. Capital Asset Advisory Services LLC now owns 3,941 shares of the medical research company’s stock worth $216,000 after acquiring an additional 182 shares during the period. Assetmark Inc. raised its position in Exact Sciences by 7.2% in the third quarter. Assetmark Inc. now owns 3,588 shares of the medical research company’s stock worth $196,000 after acquiring an additional 242 shares in the last quarter. Westside Investment Management Inc. lifted its holdings in Exact Sciences by 100.0% in the third quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 271 shares during the period. Finally, Crestwood Advisors Group LLC boosted its position in shares of Exact Sciences by 6.8% during the 2nd quarter. Crestwood Advisors Group LLC now owns 5,149 shares of the medical research company’s stock worth $274,000 after purchasing an additional 328 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Evercore set a $105.00 price target on shares of Exact Sciences and gave the company an “in-line” rating in a report on Monday, January 5th. Zacks Research lowered shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. William Blair downgraded shares of Exact Sciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 20th. Benchmark lowered Exact Sciences from a “buy” rating to a “hold” rating in a research note on Monday, November 24th. Finally, Wolfe Research cut Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Twenty-one investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Exact Sciences has an average rating of “Reduce” and an average target price of $92.13.

Exact Sciences Stock Up 0.1%

Shares of NASDAQ EXAS opened at $103.38 on Friday. The firm’s 50-day moving average is $102.48 and its two-hundred day moving average is $79.84. The company has a market capitalization of $19.73 billion, a PE ratio of -93.98, a price-to-earnings-growth ratio of 2.35 and a beta of 1.42. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $103.67. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The business’s revenue was up 23.1% compared to the same quarter last year. During the same period last year, the company earned ($0.06) EPS. Equities analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.